×
About 4,770 results

ALLMedicine™ Unstable Angina Center

Research & Reviews  1,308 results

Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.
https://doi.org/10.1056/NEJMoa2111437
The New England Journal of Medicine; Zhang W, Zhang S et. al.

Sep 8th, 2021 - The appropriate target for systolic blood pressure to reduce cardiovascular risk in older patients with hypertension remains unclear. In this multicenter, randomized, controlled trial, we assigned Chinese patients 60 to 80 years of age with hypert...

Prehospital ECG with ST-depression and T-wave inversion are associated with new onset h...
https://doi.org/10.1016/j.jelectrocard.2021.08.005
Journal of Electrocardiology; Zègre-Hemsey JK, Hogg M et. al.

Aug 31st, 2021 - Prehospital electrocardiogram(s) (ECG) can improve early detection of acute coronary syndrome (ST-segment elevation myocardial infarction [STEMI], non-STEMI, and unstable angina) and inform prehospital activation of cardiac catheterization lab; th...

Primary Prevention of CVD with Aspirin: Benefits vs Risks.
https://doi.org/10.12788/jfp.0222
The Journal of Family Practice; Weisman SM, Brunton S

Aug 26th, 2021 - Low-dose aspirin (acetylsalicylic acid [ASA]; 75 to 100 mg/d) is widely used in the prevention of cardiovascular (CV) events based on the results of large-scale studies supporting a benefit. However, questions remain regarding the benefit-risk rel...

Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial.
https://doi.org/10.1093/eurheartj/ehab557
European Heart Journal; Fernando H, Duong T et. al.

Aug 24th, 2021 - We assessed the impact of intravenous fentanyl and lignocaine on the pharmacokinetics and pharmacodynamics of ticagrelor in patients with unstable angina and non-ST-elevation myocardial infarction and their procedural analgesic efficacy and safety...

see more →

Guidelines  5 results

What's new in antiplatelet and anticoagulant therapy recommendations for unstable angin...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652660
Clinical Cardiology; Wenger NK,

Oct 17th, 2012 - This focused update addresses the use of the newly approved oral antiplatelet agents, prasugrel and ticagrelor, for the management of patients with UA/NSTEMI.

2012 Oman Heart Association simplified guidelines for the management of patients with u...
https://doi.org/10.1097/HPC.0b013e31825ac653
Critical Pathways in Cardiology; El-Deeb MH, Al Riyami AM et. al.

Jul 25th, 2012 - Although current practice guidelines provide an evidence-based approach to the management of acute coronary syndromes, application of the evidence by individual physicians has been suboptimal. This gap between comprehensive guidelines and actual p...

2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Mana...
https://doi.org/10.1016/j.jacc.2011.02.011
Journal of the American College of Cardiology; Wright RS, Anderson JL et. al.

May 7th, 2011 - 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Associa...

2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Mana...
https://doi.org/10.1161/CIR.0b013e318212bb8b
Circulation Anderson JL, Adams CD et. al.

Mar 30th, 2011 - 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Associa...

Early management of unstable angina and non-ST segment elevation myocardial infarction:...
https://doi.org/10.1136/bmj.c1134
BMJ (Clinical Research Ed.); Crowe E, Lovibond K et. al.

Mar 26th, 2010 - Early management of unstable angina and non-ST segment elevation myocardial infarction: summary of NICE guidance.|2010|Crowe E,Lovibond K,Gray H,Henderson R,Krause T,|therapy,therapeutic use,therapy,diagnosis,therapeutic use,diagnosis,

see more →

Drugs  223 results see all →

News  372 results

Apotex Corp. Issues Voluntary Nationwide Recall of Enoxaparin Sodium Injection, USP Due to Mislabeling of Syringe Barrel Measurement Markings | FDA
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/apotex-corp-issues-voluntary-nationwide-recall-enoxaparin-sodium-injection-usp-due-mislabeling

Summary Company Announcement Date: February 02, 2021 FDA Publish Date: February 03, 2021 Product Type: Drugs Reason for Announcement: Recall Reason Description Packaging error resulting in incorrect dosage listed Company Name: Apotex Corp Brand Na...

CV Benefit of Eicosapentaenoic Acid Seen at All eGFR Levels
https://www.staging.medscape.com/viewarticle/939867

Oct 27th, 2020 - Daily icosapent ethyl (Vascepa) safely and effectively reduces fatal and nonfatal ischemic events in patients with reduced kidney function, a prespecified analysis of the REDUCE-IT RENAL study shows. "Some cardiovascular drugs are not as effective...

Once Again, No Survival Benefit With PCI, Surgery in Stable CAD
https://www.medscape.com/viewarticle/933211

Jun 30th, 2020 - Coronary revascularization does not confer a survival advantage over initial medical therapy in patients with stable ischemic heart disease (SIHD) but reduces unstable angina, according to a new study-level meta-analysis. Routine upfront revascula...

Once Again, No Survival Benefit With PCI, Surgery in Stable CAD
https://www.staging.medscape.com/viewarticle/933211

Jun 30th, 2020 - Coronary revascularization does not confer a survival advantage over initial medical therapy in patients with stable ischemic heart disease (SIHD) but reduces unstable angina, according to a new study-level meta-analysis. Routine upfront revascula...

REDUCE-IT: CV Benefit of Icosapent Ethyl Directly Related to EPA Levels
https://www.medscape.com/viewarticle/928019

Apr 2nd, 2020 - The reduction in cardiovascular (CV) events seen in the REDUCE-IT trial with icosapent ethyl (Vascepa, Amarin), a high-strength formulation of purified eicosapentaenoic acid (EPA), were directly related to on-treatment serum levels of EPA, and not...

see more →